On June 1, 2025, Kura Oncology, Inc. announced that the FDA accepted its New Drug Application for ziftomenib to treat relapsed or refractory acute myeloid leukemia, with a decision expected by November 30, 2025. The application is based on promising results from a Phase 2 trial involving 92 patients, showing a complete remission rate of 23%.